KATHERINE Results Back New Adjuvant Standard for HER2+ Breast Cancer

Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.

Related Content:

SABCS Street TeamBreast CancerHER2-Positive Breast Cancer

Multi-Omics Approach to Breast Cancer May Provide Better Information Versus Biomarker Assessment Alone

Limited Efficacy, Manageable Safety Profile Found With TAS-117 to Treat Ovarian and Breast Cancer

Real-World Evidence Supports Efficacy of Palbociclib Plus Letrozole in HR+/HER2– Breast Cancer